文献速递瓣膜病与结构性心脏病

抗IL-1药物治疗复发性心包炎的系统评价与荟萃分析

Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis.
PubMed 文献 · Heart · 2021-07-12

该研究系统评价了抗IL-1药物(阿那白滞素或利洛西普)治疗复发性心包炎的安全性和有效性,纳入7项研究共397例患者(中位年龄42岁,女性60%,特发性87%)。中位随访14个月后,抗IL-1药物显著减少心包炎复发(发生率比0.06,95%CI 0.03-0.14),但不良事件风险增加(RR 5.38,95%CI 2.08-13.92),未增加严重不良事件风险。

要点

  • 抗IL-1药物可显著降低复发性心包炎复发风险(发生率比0.06)。
  • 不良事件风险增加,注射部位反应和感染发生率更高。
  • 未观察到严重不良事件风险增加。

核心结论

  • 在复发性心包炎患者中,抗IL-1药物(阿那白滞素和利洛西普)可有效预防复发,且未增加严重不良事件风险。

研究设计与样本

  • 系统评价与荟萃分析,纳入随机对照试验和观察性研究,共7项研究、397例复发性心包炎患者。

主要发现

  • 中位年龄42岁,女性占60%,特发性病因占87%。
  • 中位随访14个月(IQR 12-39),抗IL-1药物相比安慰剂和/或标准药物治疗显著降低心包炎复发(发生率比0.06,95%CI 0.03-0.14)。
  • 抗IL-1药物相比安慰剂不良事件风险增加(RR 5.38,95%CI 2.08-13.92)。
  • 注射部位反应发生在15/41(36.6%)vs 无(RR 14.98,95%CI 2.09-107.09)。
  • 感染发生在13/51(25.5%)vs 3/41(7.3%)(RR 3.65,95%CI 1.23-10.85)。

临床怎么用

  • 对于激素依赖性和秋水仙碱抵抗的复发性心包炎患者,可考虑使用抗IL-1药物以减少复发。
  • 使用抗IL-1药物时需监测注射部位反应和感染等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Corticosteroid-dependent and colchicine-resistant recurrent pericarditis (RP) is a challenging management problem, in which conventional anti-inflammatory therapy (nonsteroidal anti-inflammatory drugs, colchicine, corticosteroids) is unable to control the disease. Recent data suggest a potential role for anti-interleukin-1 (IL-1) agents for this condition. This study was designed to assess the safety and efficacy of anti-IL-1 agents in this setting. METHODS: We performed a systematic review and meta-analysis of randomised controlled trials and observational studies assessing pericarditis recurrences and drug-related adverse events in patients receiving anti-IL-1 drugs for pericarditis. RESULTS: The meta-analysis assessed 7 studies including 397 pooled patients with RP. The median age was 42 years, 60% were women and the aetiology was idiopathic in 87%. After a median follow-up of 14 months (IQR,12-39), patients receiving anti-IL-1 agents (anakinra or rilonacept) had a significantly reduction in pericarditis recurrences (incidence rate ratio 0.06, 95% CI 0.03 to 0.14), compared with placebo and/or standard medical therapy. Anti-IL-1 agents were associated with increased risk of adverse events compared with placebo (risk ratio (RR) 5.38, 95% CI 2.08 to 13.92): injection-site reactions occurred in 15/41 (36.6%) vs none (RR 14.98, 95% CI 2.09 to 107.09), infections occurred in 13/51 (25.5%) vs 3/41 (7.3%; RR 3.65, 95% CI 1.23 to 10.85). Anti-IL-1 agents were not associated with increased risk of severe adverse events. CONCLUSIONS: In patients with RP, anti-IL-1 agents (anakinra and rilonacept) are efficacious for prevention of recurrences, without severe adverse events.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Imazio M, Andreis A, Piroli F, et al. Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis. Heart. 2021. PMID: 33737453. doi:10.1136/heartjnl-2020-318869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。